XM no presta servicios a los residentes de Estados Unidos de América.
N
N

Novartis


Noticias

US court finds ‘robust’ anti-fraud safeguards in Novartis settlement

US court finds ‘robust’ anti-fraud safeguards in Novartis settlement By Mike Scarcella July 26 (Reuters) - After thousands of improper claims were detected in a $30 million settlement with Novartis, a U.S. judge in Manhattan charged with reviewing the process said there were “robust” safeguards in place to ward off fraudulent distributions.
N

Health Rounds: Researchers discover key to the placebo effect in the brain

Health Rounds: Researchers discover key to the placebo effect in the brain Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here . By Nancy Lapid July 25 (Reuters) - Hello Health Rounds Readers! Today we highlight three early experimental findings: a fascinating discovery that may help explain the placebo effect, which causes people to respond to fake drugs, and two discoveries that
N

Dren Bio To Collaborate With Novartis To Develop Novel Targeted Myeloid Engagers For Cancer

BRIEF-Dren Bio To Collaborate With Novartis To Develop Novel Targeted Myeloid Engagers For Cancer July 24 (Reuters) - Novartis AG NOVN.S : DREN BIO ANNOUNCES STRATEGIC COLLABORATION WITH NOVARTIS TO DEVELOP NOVEL TARGETED MYELOID ENGAGERS FOR CANCER DREN BIO, INC. : ELIGIBLE TO RECEIVE UP TO $2.85 BILLION IN ADDITIONAL CASH PAYMENTS DREN BIO : TO G
N

Pharma aims to deliver personalized cancer therapies more quickly

FOCUS-Pharma aims to deliver personalized cancer therapies more quickly By Michael Erman NEW YORK, July 24 (Reuters) - Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient's disease course.
G
N

Drug giants eye China for deals despite growing Sino-US tensions

ANALYSIS-Drug giants eye China for deals despite growing Sino-US tensions Bristol Myers Squibb, Sanofi looking at China M&A -employees AstraZeneca, Novartis have done China deals this year Political risks are a consideration -analysts By Andrew Silver and Kane Wu SHANGHAI/HONG KONG, July 23 (Reuters) - Some of the biggest global drugmakers, undeterred by mounting Sino-U.S.
A
N
S

Novartis AG reports results for the quarter ended in June - Earnings Summary

Novartis AG reports results for the quarter ended in June - Earnings Summary Novartis AG NVS.N reported quarterly adjusted earnings of $1.97​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.83. The mean expectation of eight analysts for the quarter was for earnings of $1.89 per share.
N

Novartis AG reports results for the quarter ended in June - Earnings Summary

Novartis AG reports results for the quarter ended in June - Earnings Summary Novartis AG NOVN.S reported quarterly adjusted earnings of $1.97​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.83. The mean expectation of ten analysts for the quarter was for earnings of $1.87 per share.
N

Tech seeking a floor after selloff

CORRECTED-LIVE MARKETS-Tech seeking a floor after selloff Corrects para 2 to "up" instead of "down" Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com TECH SEEKING A FLOOR AFTER SELLOFF European shares were expected to steady at the open on Thursday after three days of losses, as a sharp rotation move out of high-flying Big Tech stocks looked set for a breather.
N
N
V
A
E
F
U
G

Novartis CFO: Launch Of Cosentyx In Hidradenitis Suppurativa Going Beyond Our Expectations

BRIEF-Novartis CFO: Launch Of Cosentyx In Hidradenitis Suppurativa Going Beyond Our Expectations July 18 (Reuters) - Novartis AG NOVN.S : NOVARTIS CFO SAYS LAUNCH OF COSENTYX TO TREAT HIDRADENITIS SUPPURATIVA GOING BEYOND OUR EXPECTATIONS Further company coverage: NOVN.S
N

Novartis lifts profit forecast for second time on Cosentyx, Entresto

CORRECTED-UPDATE 2-Novartis lifts profit forecast for second time on Cosentyx, Entresto Corrects to $800 million, not billion, in paragraph 6 By Ludwig Burger FRANKFURT, July 18 (Reuters) - Swiss drugmaker Novartis NOVN.S raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis drug Cosentyx .
N

Novartis raises 2024 profit guidance for second time

Novartis raises 2024 profit guidance for second time FRANKFURT, July 18 (Reuters) - Swiss drugmaker Novartis NOVN.S raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions of drugs including heart failure treatment Entresto and Kesimpta for multiple sclerosis. It said in a statement that full-year adjusted operating income is expected to grow by a "mid- to high teens" percentage, where it had previously seen a "low double-digit to mid-teens" percentag
N

Swiss stocks - Factors to watch on July 18

Swiss stocks - Factors to watch on July 18 ZURICH/GDANSK, July 18(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ABB ABBN.S The company reported a Q2 revenue of USD 8.24 billion NOVARTIS NOVN.S The company raised its guidance for its core operating income, expecting growth of mid- to high teens. VAT Group VACN.S The company says its H1 EBITDA is up, at CHF 135 million ROCHE ROG.S The company's Vabysmo study met all primary endpoints SFS Group SFSN.S The gr
A
N
R
S

Novartis AG <NVS.N> expected to post earnings of $1.89 a share - Earnings Preview

Novartis AG expected to post earnings of $1.89 a share - Earnings Preview Novartis AG NVS.N , NVS is expected to show a fall in quarterly revenue when it reports results on July 18 for the period ending June 30 2024 The Basel Basel-stadt-based company is expected to report a 9.2% decrease in revenue to $12.375 billion from $13.62 billion a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
N

Novartis AG <NOVN.S> expected to post earnings of $1.87 a share - Earnings Preview

Novartis AG expected to post earnings of $1.87 a share - Earnings Preview Novartis AG NOVN.S is expected to show a fall in quarterly revenue when it reports results on July 18 for the period ending June 30 2024 The Basel Basel-stadt-based company is expected to report a 9.2% decrease in revenue to $12.362 billion from $13.62 billion a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
N

Law firm Milberg skirts sanctions over fake claims in credit card fees case

Law firm Milberg skirts sanctions over fake claims in credit card fees case By Mike Scarcella July 15 (Reuters) - A law firm that said it unknowingly submitted fake claims as part of a $5.6 billion antitrust settlement with Visa and Mastercard will escape sanctions for now, a federal magistrate judge has ruled. U.S. Magistrate Judge Joseph Marutollo in Brooklyn said on Saturday that punishing plaintiffs law firm Milberg Coleman Bryson Phillips Grossman was “unnecessary at this time” after th
N
V

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds Unilever July 15 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO.HE : The Finnis
B
B
B
B
C
I
M
N
T
T
U
V
B
U

China c.bank seen holding medium-term lending rate steady Monday

RPT-China c.bank seen holding medium-term lending rate steady Monday Repeats story from Friday with no changes to text SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed.
B
N

China c.bank seen holding medium-term lending rate steady Monday

RPT-China c.bank seen holding medium-term lending rate steady Monday Repeats story from Friday with no changes to text SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed.
B
N

China c.bank seen holding medium-term lending rate steady Monday

China c.bank seen holding medium-term lending rate steady Monday SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed. While the economy continues to sputter, a weak Chinese currency has remained the key constraint limiting Beijing's monetary easing efforts, as that could further widen the yield gap with oth
B
N

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds details on fresh job cuts July 9 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO
B
B
B
B
C
I
M
N
T
T
U
V
B
U



Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.